

(Under Corporate Insolvency Resolution Process)

May 14, 2019

**National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th Floor, Plot No:
C/1 G - Block, Bandra - Kurla Complex
Bandra (East),
Mumbai – 400 051.**

**BSE Limited
Corporate Relationship Department
1st floor, New Trading Ring
Rotunda Building, P J Towers
Dalal Street, Fort
Mumbai - 400 001.**

Dear Sir/Madam,


In accordance with the requirements of the Listing Regulations 2015, we would like to inform you that Orchid has received ANDA approval from US FDA for Risedronate Sodium Tablets USP, 30 mg and 35 mg today.

Risedronate sodium tablets are a bisphosphonate indicated for the treatment and prevention of Osteoporosis.

Kindly take the above information on your records.

Thanking you,

Yours faithfully,



**L Chandrasekar
Executive V P – Finance & Secretary**